MCID: SYS065
MIFTS: 18

Systemic Lupus Erythematosus 11

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 11

MalaCards integrated aliases for Systemic Lupus Erythematosus 11:

Name: Systemic Lupus Erythematosus 11 54 71
Sleb11 71

Classifications:



External Ids:

OMIM 54 612253
MedGen 40 C2677096
MeSH 42 D008180

Summaries for Systemic Lupus Erythematosus 11

UniProtKB/Swiss-Prot : 71 Systemic lupus erythematosus 11: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

MalaCards based summary : Systemic Lupus Erythematosus 11, is also known as sleb11. An important gene associated with Systemic Lupus Erythematosus 11 is STAT4 (Signal Transducer And Activator Of Transcription 4). The drugs Hydroxychloroquine and Immunosuppressive Agents have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and kidney.

Description from OMIM: 612253

Symptoms & Phenotypes for Systemic Lupus Erythematosus 11

Clinical features from OMIM:

612253

Drugs & Therapeutics for Systemic Lupus Erythematosus 11

Drugs for Systemic Lupus Erythematosus 11 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 4 118-42-3 3652
2 Immunosuppressive Agents Phase 4,Phase 2
3 Angiogenesis Inhibitors Phase 4
4 Angiogenesis Modulating Agents Phase 4
5 Anti-Bacterial Agents Phase 4
6 Anti-Infective Agents Phase 4
7 Antimalarials Phase 4
8 Antiparasitic Agents Phase 4
9 Antiprotozoal Agents Phase 4
10 Antirheumatic Agents Phase 4
11 Pharmaceutical Solutions Phase 3,Phase 1
12
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
13 Vaccines Phase 2,Phase 1
14 Antibodies Phase 2,Phase 1
15 Antibodies, Monoclonal Phase 2,Phase 1
16 Immunoglobulins Phase 2,Phase 1
17
Cholecalciferol Approved, Nutraceutical 67-97-0 6221 10883523 5280795
18
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
19 Bone Density Conservation Agents
20 Micronutrients
21 Trace Elements
22 Vitamins
23 Omega 3 Fatty Acid Nutraceutical
24 Calciferol Nutraceutical

Interventional clinical trials:

(show all 16)

id Name Status NCT ID Phase Drugs
1 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Not yet recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
2 Study of LJP 394 in Lupus Patients With History of Renal Disease Terminated NCT00089804 Phase 3 abetimus sodium (LJP 394) and/or placebo solution;abetimus sodium (LJP 394);Phosphate-buffered saline
3 Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy. Unknown status NCT01687192 Phase 2
4 Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Completed NCT01534403 Phase 2
5 Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Completed NCT01449071 Phase 1, Phase 2
6 Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus Recruiting NCT02908100 Phase 2 GDC-0853 (high dose);GDC-0853 (low dose);Placebo
7 Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC) Terminated NCT01738360 Phase 2 Arsenic trioxide
8 Zostavax in Systemic Lupus Erythematosus Completed NCT01474720 Phase 1 Zostavax vaccine
9 Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus Completed NCT01764594 Phase 1
10 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01686555 Phase 1 ABT-199
11 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus Completed NCT02106897 Phase 1 BIIB059;Placebo
12 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus Not yet recruiting NCT02920424 Phase 1 JNJ-56022473;Placebo
13 Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE) Unknown status NCT01460680
14 Long-term Immunogenicity of a HPV Vaccine in SLE Completed NCT02477254
15 Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. Completed NCT01892748 Cholecalciferol;Placebo
16 Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE) Recruiting NCT02782039

Search NIH Clinical Center for Systemic Lupus Erythematosus 11

Genetic Tests for Systemic Lupus Erythematosus 11

Anatomical Context for Systemic Lupus Erythematosus 11

MalaCards organs/tissues related to Systemic Lupus Erythematosus 11:

39
Bone, Skin, Kidney, Bone Marrow

Publications for Systemic Lupus Erythematosus 11

Variations for Systemic Lupus Erythematosus 11

ClinVar genetic disease variations for Systemic Lupus Erythematosus 11:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 STAT4 NM_003151.3(STAT4): c.274-23582A= single nucleotide variant risk factor rs7574865 GRCh37 Chromosome 2, 191964633: 191964633

Expression for Systemic Lupus Erythematosus 11

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 11.

Pathways for Systemic Lupus Erythematosus 11

GO Terms for Systemic Lupus Erythematosus 11

Sources for Systemic Lupus Erythematosus 11

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....